Chiasma Receives Orphan Drug Designation From the FDA for Octreolin(TM) for the Oral Treatment of Acromegaly

Chiasma Receives Orphan Drug Designation From the FDA for Octreolin(TM) for the Oral Treatment of Acromegaly
NEW YORK and JERUSALEM, June 28 /PRNewswire/ — Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration (FDA) has granted orphan drug designation for Chiasma’s investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company’s proprietary Transient Permeability Enhancer (TPE) technology for the oral treatment of acromegaly …
Read more on redOrbit

Chiasma Receives Orphan Drug Designation From the FDA for Octreolin for the Oral Treatment of Acromegaly
Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma’s investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company’s proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth …
Read more on PR Newswire via Yahoo! Finance